bioMerieux


Q3 beat; promising growth across the key offerings

30/10/24 -"bioMerieux’s Q3 organic sales were a beat. The double-digit growth was driven by a healthy contribution from both segments. While the 2024 guidance remained unchanged, investors rejoiced at the ..."

Pages
61
Language
English
Published on
30/10/24
You may also be interested by these reports :
31/10/24
Amplifon’s Q3 profitability missed the market’s expectations. The mid-single-digit organic sales growth was driven by growth across all regions. ...

30/10/24
bioMerieux’s Q3 organic sales were a beat. The double-digit growth was driven by a healthy contribution from both segments. While the 2024 guidance ...

30/10/24
Clariane’s turnover growth continued to be driven by increases in both volume and pricing across all the business segments and regions. The group ...

30/10/24
Drägerwerk’s Q3 24 numbers were exactly in line with the prelims. Sales were down, with declines across both segments. However, with a book-to-bill ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO